+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Alport Syndrome Market by Product (Diagnosis, Treatments), Genetic Type (Autosomal Dominant Alport Syndrome, Autosomal Recessive Alport Syndrome, X-linked Alport Syndrome), End-Use - Forecast 2024-2030- Product Image
Global Alport Syndrome Market by Product (Diagnosis, Treatments), Genetic Type (Autosomal Dominant Alport Syndrome, Autosomal Recessive Alport Syndrome, X-linked Alport Syndrome), End-Use - Forecast 2024-2030- Product Image
Sale

Global Alport Syndrome Market by Product (Diagnosis, Treatments), Genetic Type (Autosomal Dominant Alport Syndrome, Autosomal Recessive Alport Syndrome, X-linked Alport Syndrome), End-Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924757
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Alport Syndrome Market size was estimated at USD 1.59 billion in 2023, USD 1.77 billion in 2024, and is expected to grow at a CAGR of 11.54% to reach USD 3.43 billion by 2030.

Alport syndrome is a genetic condition indicated by hearing loss, kidney disease, and eye abnormalities. It is caused by mutations in the genes responsible for producing collagen in the kidneys, eyes, and inner ears, which leads to progressive loss of kidney function as well as sensory deficits. Increase in genetic research and understanding of Alport Syndrome mechanisms for advancements in genetic testing and diagnostic solutions driving the market growth. Moreover, increasing prevalence of genetic disorders across the globe owing to the market expansion. However, the Alport syndrome market faces several limitations, such as the complexity of the genetic basis of the disease, which makes drug development difficult. The small patient population limits the potential for large-scale clinical trials, and diverse genetic mutations require bespoke treatment approaches, increasing development costs and complexity. Furthermore, recent advancements in gene therapy and stem cell research offer potential opportunities for the development of new treatments for Alport Syndrome. Additionally, growing investment in rare disease research also presents opportunities for market expansion.

Regional Insights

The American region represents a significant market for Alport Syndrome treatments due to its advanced healthcare system and higher awareness about genetic disorders. Consumers across the region show a preference for newer treatment options that promise better efficacy and fewer side effects. There is a substantial level of investment in genetic research to support the research initiatives by governments and the private sector. European Union countries demonstrate distinct healthcare systems and variable access to treatments for rare diseases, including Alport Syndrome. EU legislation encourages the development of treatments for rare diseases, which has led to increased investment and research. European consumers benefit from facilitating access to diagnosis and treatment for rare diseases across member states. In the Middle East, countries such as Saudi Arabia have invested heavily in healthcare infrastructure and offer specialized services for rare disorders, suggesting a growing market for treatments. APAC region's massive population and improving healthcare system suggest potential growth for the Alport Syndrome treatment market. The government's increasing support for healthcare and focus on tackling rare diseases. Additionally, APAC countries' growing pharmaceutical sector actively seeks patents on new treatments, investing in both research and development.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alport Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alport Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alport Syndrome Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Calliditas Therapeutics AB, CENTOGENE N.V., Chinook Therapeutics Inc., Daiichi Sankyo Company, Limited, Eloxx Pharmaceuticals, Inc., Eurofins Scientific SE, GlaxoSmithKline PLC, Illumina Inc, Invitae Corp., Merck & Co., Inc., Mylan N.V., Natera, Inc., Oxalo Therapeutics, Pfizer Inc., Quest Diagnostics Incorporated, Reata Pharmaceuticals, Inc. by Biogen Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Travere Therapeutics, Inc.

Market Segmentation & Coverage

This research report categorizes the Alport Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Diagnosis
      • Blood Test
      • Genetic Test
      • Kidney Biopsy
    • Treatments
      • Medications
      • Surgery
  • Genetic Type
    • Autosomal Dominant Alport Syndrome
    • Autosomal Recessive Alport Syndrome
    • X-linked Alport Syndrome
  • End-Use
    • Diagnostic Centers & Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Alport Syndrome Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alport Syndrome Market?
  3. What are the technology trends and regulatory frameworks in the Alport Syndrome Market?
  4. What is the market share of the leading vendors in the Alport Syndrome Market?
  5. Which modes and strategic moves are suitable for entering the Alport Syndrome Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Alport Syndrome Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of genetic disorders across the globe
5.1.1.2. Ongoing advancements in genetic diagnostic solutions for Alport syndrome
5.1.1.3. Emerging new treatments and therapies in clinical trials
5.1.2. Restraints
5.1.2.1. High costs associated with surgeries and treatment processes for Alport syndrome
5.1.3. Opportunities
5.1.3.1. Increase in the number of research and development activities
5.1.3.2. Growing investment in rare disease research from public & private sectors
5.1.4. Challenges
5.1.4.1. Complexities associate of the genetic based drug developments
5.2. Market Segmentation Analysis
5.2.1. Product: Rising research and development for innovations in early diagnosis solutions of Alport Syndrome
5.2.2. Genetic Type: Ongoing therapeutic advancements in X-linked Alport Syndrome due to its rising prevalence
5.2.3. End-Use: Expansion in hospitals & clinics activities to provide extensive range treatment and disease management
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Alport Syndrome Market, by Product
6.1. Introduction
6.2. Diagnosis
6.3.1. Blood Test
6.3.2. Genetic Test
6.3.3. Kidney Biopsy
6.3. Treatments
6.4.1. Medications
6.4.2. Surgery
7. Alport Syndrome Market, by Genetic Type
7.1. Introduction
7.2. Autosomal Dominant Alport Syndrome
7.3. Autosomal Recessive Alport Syndrome
7.4. X-linked Alport Syndrome
8. Alport Syndrome Market, by End-Use
8.1. Introduction
8.2. Diagnostic Centers & Laboratories
8.3. Hospitals & Clinics
9. Americas Alport Syndrome Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Alport Syndrome Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Alport Syndrome Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. New Product Launch & Enhancement
12.3.1.1. Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
12.3.2. Award, Recognition, & Expansion
12.3.2.1. Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AstraZeneca PLC
13.1.2. Boehringer Ingelheim International GmbH
13.1.3. Calliditas Therapeutics AB
13.1.4. CENTOGENE N.V.
13.1.5. Chinook Therapeutics Inc.
13.1.6. Daiichi Sankyo Company, Limited
13.1.7. Eloxx Pharmaceuticals, Inc.
13.1.8. Eurofins Scientific SE
13.1.9. GlaxoSmithKline PLC
13.1.10. Illumina Inc
13.1.11. Invitae Corp.
13.1.12. Merck & Co., Inc.
13.1.13. Mylan N.V.
13.1.14. Natera, Inc.
13.1.15. Oxalo Therapeutics
13.1.16. Pfizer Inc.
13.1.17. Quest Diagnostics Incorporated
13.1.18. Reata Pharmaceuticals, Inc. by Biogen Inc.
13.1.19. Sanofi S.A.
13.1.20. Teva Pharmaceutical Industries Ltd.
13.1.21. Travere Therapeutics, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. ALPORT SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. ALPORT SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. ALPORT SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ALPORT SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ALPORT SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ALPORT SYNDROME MARKET DYNAMICS
FIGURE 7. ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2023 VS 2030 (%)
FIGURE 10. ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ALPORT SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. ALPORT SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ALPORT SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ALPORT SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. ALPORT SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ALPORT SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALPORT SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 8. ALPORT SYNDROME MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ALPORT SYNDROME MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ALPORT SYNDROME MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 13. ALPORT SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ALPORT SYNDROME MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 16. ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL DOMINANT ALPORT SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL RECESSIVE ALPORT SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ALPORT SYNDROME MARKET SIZE, BY X-LINKED ALPORT SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 20. ALPORT SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ALPORT SYNDROME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 38. CANADA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. CANADA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 40. CANADA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 41. CANADA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 42. CANADA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. MEXICO ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 46. MEXICO ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 47. MEXICO ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 65. CHINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. CHINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 67. CHINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 68. CHINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 69. CHINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 70. INDIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. INDIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 72. INDIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 73. INDIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 74. INDIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 80. JAPAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 81. JAPAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 82. JAPAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 83. JAPAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 84. JAPAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 90. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 95. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 100. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 105. TAIWAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 110. THAILAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. THAILAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 112. THAILAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 113. THAILAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 114. THAILAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. VIETNAM ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. DENMARK ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 127. DENMARK ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 128. DENMARK ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 129. DENMARK ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 130. DENMARK ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 131. EGYPT ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. EGYPT ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 133. EGYPT ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 134. EGYPT ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 135. EGYPT ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 136. FINLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. FINLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 138. FINLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 139. FINLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 140. FINLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 141. FRANCE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 142. FRANCE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 146. GERMANY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 147. GERMANY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 148. GERMANY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 149. GERMANY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 156. ITALY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. ITALY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 158. ITALY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 159. ITALY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 171. NORWAY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. NORWAY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 173. NORWAY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 174. NORWAY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 175. NORWAY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 176. POLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. POLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 178. POLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. POLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 180. POLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 181. QATAR ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 182. QATAR ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 183. QATAR ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 184. QATAR ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 185. QATAR ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 201. SPAIN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 202. SPAIN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 204. SPAIN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 211. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 212. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 213. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 216. TURKEY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 217. TURKEY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 218. TURKEY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 219. TURKEY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 220. TURKEY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 231. ALPORT SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 232. ALPORT SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 233. ALPORT SYNDROME MARKET LICENSE & PRICING

Companies Mentioned

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Calliditas Therapeutics AB
  • CENTOGENE N.V.
  • Chinook Therapeutics Inc.
  • Daiichi Sankyo Company, Limited
  • Eloxx Pharmaceuticals, Inc.
  • Eurofins Scientific SE
  • GlaxoSmithKline PLC
  • Illumina Inc
  • Invitae Corp.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Natera, Inc.
  • Oxalo Therapeutics
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Reata Pharmaceuticals, Inc. by Biogen Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Travere Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.43 Billion
Compound Annual Growth Rate11.5%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Alport Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Alport Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 178 Pages
  • Global
From
Alport Syndrome - Pipeline Insight, 2024 - Product Image

Alport Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Autosomal dominant polycystic kidney disease - Pipeline Insight, 2024 - Product Image

Autosomal dominant polycystic kidney disease - Pipeline Insight, 2024

  • Clinical Trials
  • 75 Pages
  • Global
From
Global Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Forecast 2024-2030 - Product Image

Global Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Hepatorenal Syndrome Treatment Global Market Report 2024 - Product Image

Hepatorenal Syndrome Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.